Cambrex is a global market leader in branded and generic small molecule active pharmaceutical ingredients (APIs), advanced intermediates, custom development and manufacturing and controlled substances. Our pharmaceutical products, technologies and expertise accelerate your small molecule therapeutics into the market.

Employee Rating

2.6More
TypePublic
HQEast Rutherford, US
Founded1981
Size (employees)1,228 (est)
Websitecambrex.com
Cambrex was founded in 1981 and is headquartered in East Rutherford, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Cambrex

Shawn P. Cavanagh

Shawn P. Cavanagh

Executive Vice President and Chief Operating Officer
Tom Vadaketh

Tom Vadaketh

Executive Vice President and Chief Financial Officer
Show more

Cambrex Office Locations

Cambrex has an office in East Rutherford
East Rutherford, US (HQ)
1 Meadowlands Plaza
Show all (1)
Report incorrect company information

Cambrex Financials and Metrics

Cambrex Revenue

Embed Graph
View revenue for all periods
Cambrex's revenue was reported to be $523.94 m in FY, 2017
USD

Revenue (Q3, 2018)

104.0m

Gross profit (Q3, 2018)

32.1m

Gross profit margin (Q3, 2018), %

30.9%

Net income (Q3, 2018)

26.7m

EBIT (Q3, 2018)

6.6m

Market capitalization (14-Dec-2018)

1.4b

Closing stock price (14-Dec-2018)

41.6

Cash (30-Sep-2018)

97.1m

EV

1.6b
Cambrex's current market capitalization is $1.4 b.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

315.9m431.9m489.2m523.9m

Cost of goods sold

215.3m256.4m286.4m304.4m

Gross profit

100.6m175.5m202.8m219.6m

Gross profit Margin, %

32%41%41%42%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

77.4m65.6m97.3m80.6m77.7m106.0m91.7m93.4m118.2m99.3m103.1m133.8m112.0m138.9m147.0m104.0m

Cost of goods sold

52.5m49.5m64.5m52.9m48.4m60.7m57.3m55.8m70.1m61.8m58.2m77.1m65.7m90.2m87.3m71.9m

Gross profit

25.0m16.1m32.9m27.7m29.3m45.3m34.4m37.6m48.1m37.5m44.9m56.8m46.3m48.7m59.8m32.1m

Gross profit Margin, %

32%25%34%34%38%43%38%40%41%38%44%42%41%35%41%31%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

22.7m45.5m44.0m74.1m183.3m

Accounts Receivable

12.9m10.6m7.3m6.7m

Inventories

90.0m8.7m109.9m123.2m138.5m

Current Assets

202.6m227.6m259.3m322.7m422.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

25.9m57.3m57.2m81.7m102.5m

Depreciation and Amortization

22.5m23.8m22.1m24.7m31.8m

Inventories

(19.3m)(9.1m)(32.7m)(23.7m)(13.3m)

Accounts Payable

10.1m12.4m10.3m1.8m(20.1m)
Quarterly
USDY, 2018

EV/EBIT

245.1 x

EV/CFO

40.9 x

EV/FCF

-429.9 x

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information

Cambrex News and Updates

Cambrex Expands Analytical Capabilities at its High Point, NC Site

EAST RUTHERFORD, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it is investing $1 million at its High Point, NC site…

Small Molecule API Market 2018: Global Analysis by Key Players – Albemarle, Allergan, Cambrex, GlaxoSmithKline, Lonza

Wiseguyreports.Com Publish New Market Research Report On -“Small Molecule API Market - Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2018 - 2027” Posted via Industry Today. Follow us on Twitter @IndustryToday

Cambrex to Acquire Avista Pharma Solutions, Adding Early Stage API and Finished Dosage Form Development & Testing Services to its Global Contract Development & Manufacturing Network

-- Conference Call at 8:30 a.m. ET Today -- EAST RUTHERFORD, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced it has …

Cambrex to Announce Third Quarter 2018 Financial Results on November 8, 2018

EAST RUTHERFORD, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that third quarter 2018 financial results will be released…
Report incorrect company information

Cambrex Blogs

Cambrex Invests c.$3 Million to Upgrade Generic API Manufacturing Facilities at Milan, Italy Site

East Rutherford, NJ – October 8, 2018 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it is investing approximately $3 million to increase the capacity and ef…

Cambrex to present at upcoming investor conferences in September

East Rutherford, NJ – August 29, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that company management will present at the following investor conferences in September: 2018 Wells Fargo …

Cambrex to Announce Second Quarter 2018 Financial Results on August 2, 2018

East Rutherford, N.J., July 27, 2018 (GLOBE NEWSWIRE) – Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that second quarter 2018 financial results will be released on Thursday, August 2, 2018 bef…

Cambrex to Acquire Halo Pharma, Adding Drug Development and Finished Dosage Capabilities to Global API Manufacturing Network

— Conference Call at 8:30 a.m. ET Today — East Rutherford, NJ – July 23, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced it has entered into a definitive agreement to acquire Halo Pharma …

Cambrex Expands Generic API Research and Development Capabilities at Milan, Italy Site

East Rutherford, NJ – June 12, 2018 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it will expand research and development capabilities at its site in Paullo, Milan, Italy. The investm…

Cambrex To Present At The Jefferies 2018 Global Healthcare Conference

East Rutherford, NJ – June 1, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcar…
Show more

Cambrex Company Life and Culture

Report incorrect company information

Cambrex Frequently Asked Questions

  • When was Cambrex founded?

    Cambrex was founded in 1981.

  • Who are Cambrex key executives?

    Cambrex's key executives are Shawn P. Cavanagh and Tom Vadaketh.

  • How many employees does Cambrex have?

    Cambrex has 1,228 employees.

  • What is Cambrex revenue?

    Latest Cambrex annual revenue is $523.9 m.

  • What is Cambrex revenue per employee?

    Latest Cambrex revenue per employee is $426.7 k.

  • Who are Cambrex competitors?

    Competitors of Cambrex include Lonza, Assertio Therapeutics and Aradigm.

  • Where is Cambrex headquarters?

    Cambrex headquarters is located at 1 Meadowlands Plaza, East Rutherford.

  • Where are Cambrex offices?

    Cambrex has an office in East Rutherford.

  • How many offices does Cambrex have?

    Cambrex has 1 office.